Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population. It has been demonstrated that overexpression of Bruton’s tyrosine kinase (BTK)...

Full description

Bibliographic Details
Main Authors: Weam Othman Elbezanti, Omar S. Al-Odat, Robert Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
Bruton’s tyrosine kinase
Btk inhibitor
multiple myeloma
hematological malignancies
multiple myeloma stem cell-like cells
acquired mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.894535/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.894535/full

Similar Items